ANX 042

Drug Profile

ANX 042

Alternative Names: ANX042

Latest Information Update: 19 Jan 2017

Price : $50

At a glance

  • Originator Mayo Clinic
  • Developer Anexon
  • Class Heart failure therapies; Natriuretic peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Heart failure; Kidney disorders

Most Recent Events

  • 01 Jan 2017 Mayo Clinic, National Institutes of Health and National Heart, Lung, and Blood Institute initiate the phase Ib ANX-042 Aim 1 trial for Heart failure and Kidney disorders in USA (IV, Infusion) (NCT03019653)
  • 19 Apr 2016 No recent reports on development identified - Phase-I for Heart failure (In volunteers) in USA (IV)
  • 19 Apr 2016 No recent reports on development identified - Phase-I for Kidney disorders (In volunteers) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top